Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations
about
Polymorphisms and HNPCC: PMS2-MLH1 protein interactions diminished by single nucleotide polymorphismsThe molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptorStructural basis for antagonism and resistance of bicalutamide in prostate cancerStructure and function of steroid receptor AF1 transactivation domains: induction of active conformationsElectrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifsStructure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC)Selective androgen receptor modulators in preclinical and clinical developmentComparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinityExpanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs)Chemistry and structural biology of androgen receptorRecognition and accommodation at the androgen receptor coactivator binding interfaceInteraction of organophosphate pesticides and related compounds with the androgen receptorTherapeutic androgen receptor ligands.Dichotomy in the Epigenetic Mark Lysine Acetylation is Critical for the Proliferation of Prostate Cancer CellsTargeting the androgen receptor with steroid conjugatesCrystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosteroneThe three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonismCrystal Structure of the T877A Human Androgen Receptor Ligand-binding Domain Complexed to Cyproterone Acetate Provides Insight for Ligand-induced Conformational Changes and Structure-based Drug DesignModulation of Androgen Receptor Activation Function 2 by Testosterone and DihydrotestosteroneStructural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12Doubling the Size of the Glucocorticoid Receptor Ligand Binding Pocket by DeacylcortivazolIdentification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen ReceptorX-ray Structures of Progesterone Receptor Ligand Binding Domain in Its Agonist State Reveal Differing Mechanisms for Mixed Profiles of 11 -Substituted SteroidsAndrogen Receptor: A Complex Therapeutic Target for Breast CancerPlant-derived 3,3'-Diindolylmethane is a strong androgen antagonist in human prostate cancer cellsThe FXXLF motif mediates androgen receptor-specific interactions with coregulators3D model of lamprey estrogen receptor with estradiol and 15alpha-hydroxy-estradiolGene changes may minimize masculinizing and defeminizing influences of exposure to male cotwins in female callitrichine primates.Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.The use of phage display technique for the isolation of androgen receptor interacting peptides with (F/W)XXL(F/W) and FXXLY new signature motifs.Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer.Structural analysis of the evolution of steroid specificity in the mineralocorticoid and glucocorticoid receptors.Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugsBeta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcriptionThe fate of the duplicated androgen receptor in fishes: a late neofunctionalization event?Androgen receptor mutations associated with androgen insensitivity syndrome: a high content analysis approach leading to personalized medicineThe helix 1-3 loop in the glucocorticoid receptor LBD is a regulatory element for FKBP cochaperones.A new strategy for selective targeting of progesterone receptor with passive antagonists.Expression, purification and primary crystallographic study of human androgen receptor in complex with DNA and coactivator motifs.Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H.
P2860
Q24292177-AF515DC5-3FAA-48FB-AC9E-47F95625FAFDQ24316455-B0FE66CD-1B66-4938-A4B7-92EFF00EDF63Q24523708-858B6F10-6415-4C10-A6BC-1B7B19D74880Q24537137-824BA71B-2E74-49FA-81E8-2DCBB06EDE86Q24550576-018176BC-6E52-4C58-B7ED-DDBEC77840C4Q24635639-36CBA243-DBFC-40FF-91D0-D0C84CAC23ADQ24645579-01F7D78A-B08D-4E14-BE67-15B08BA99870Q24647922-1C5CD3E7-AEDB-4396-8C29-A4ACDA0BD7FBQ24680340-7CF71C69-2FEB-4DC8-BF40-65F86AF6950BQ24685498-68C41B9E-A801-42C2-930E-5EF9A9CEEBDFQ24799399-D08E8E27-0359-4B59-B4F4-33590F296CD1Q24814312-87AAFF04-4C98-410B-9BA0-6A5FB940CFB3Q25257846-F4AAD1B4-5CF6-448F-AC04-08EFDCC6E4C4Q26795738-7CDA1F8F-4DDD-41C5-B533-E72EC9A6A4E6Q26995692-85EEE664-B726-4A17-9E67-C33283927391Q27631345-72C023EE-E33E-468C-BDA5-8B8C2E722594Q27640953-25F96527-4203-4E3D-AB81-CA438F51F35DQ27643866-028A7CD2-FB04-4F9D-8232-1804706F1491Q27646416-ABD64A6D-B057-4F7B-B554-3715A6500E24Q27647445-F19BEA4C-503C-4C85-BB9D-24EA583D2BFCQ27649439-9DB1CEB0-93F1-4F5C-9290-02F063532A8CQ27659041-A89B0772-F62E-4327-B268-A7261A0D7808Q27678748-47E222D3-46D6-49B8-BA85-EA95FAE097FDQ28075188-CCD45557-F99A-45A0-A050-715DC3E50BFFQ28187403-DA188F2A-F634-43AA-B21A-97ED880C38E5Q28214781-CDF2CE2F-3414-4188-927F-35B784D8CF1DQ28475661-845E7D77-E556-46BE-964D-E823284CB1D4Q30388880-995DDDCF-6A2F-484F-AC75-D4E73EAFB52AQ30418832-EFFB43DB-B2B9-44E5-9E7D-7DD96B2E10BAQ31140532-59247C15-64E4-4BC9-8CB6-30E3D4E4AEB5Q31527864-73EE3A7C-5097-4B3E-B7D5-ABC15AAF70A7Q33274265-DA9E3966-6E18-4149-B234-ECB63F7F02DEQ33289718-C445B7A7-3342-44D5-A25D-6391CCDB93FCQ33292178-AE5DF0C6-12B5-40D4-882A-FEA9A072D80FQ33394368-73F6174C-EA73-441C-9764-6B4D6F43A5D7Q33518450-2BDD83C5-A0DD-495A-AF5D-510616B70A51Q33633104-C0DFF322-87F5-4BA6-9EF1-2C2DA2BCBCD7Q33633141-30C8B464-94CC-4BC5-98D6-80CB3DBA45CFQ33695597-8E2EDAF0-C513-42AD-8936-E84FB66B7561Q33717757-8F63C4F4-C2CD-49F5-9983-B374346F2DFE
P2860
Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Structural evidence for ligand ...... for pathogenic gene mutations
@ast
Structural evidence for ligand ...... for pathogenic gene mutations
@en
Structural evidence for ligand ...... for pathogenic gene mutations
@nl
type
label
Structural evidence for ligand ...... for pathogenic gene mutations
@ast
Structural evidence for ligand ...... for pathogenic gene mutations
@en
Structural evidence for ligand ...... for pathogenic gene mutations
@nl
prefLabel
Structural evidence for ligand ...... for pathogenic gene mutations
@ast
Structural evidence for ligand ...... for pathogenic gene mutations
@en
Structural evidence for ligand ...... for pathogenic gene mutations
@nl
P2093
P2860
P3181
P356
P1476
Structural evidence for ligand ...... for pathogenic gene mutations
@en
P2093
M A Carrondo
P M Matias
P2860
P304
P3181
P356
10.1074/JBC.M004571200
P407
P577
2000-08-25T00:00:00Z